OPU
IBER.U

Omni Partners US’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Omni Partners US’s Portfolio IBER.U Stock Details IBER.U Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$3.83M Buy
383,033
+18,662
+5% +$186K 0.2% 96
2021
Q2 		$3.66M Buy
+364,371
New +$3.65M 0.16% 63

Other funds holding IBER.U

HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return

Omni Partners US's IBER.U Position: Q3 2021 in Review

Omni Partners US increased its Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) stake by 5.1% in Q3 2021, buying an estimated $186K and bringing the position to 383,033 shares worth $3.83M. The position accounts for 0.2% of the portfolio, ranked #96.

Omni Partners US first reported a position in IBER.U in Q2 2021 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold IBER.U as of Q3 2021.

  • Omni Partners US held 383,033 shares of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant worth $3.83M as of Q3 2021.
  • Omni Partners US bought 18,662 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q3 2021, an estimated $186K.
  • Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant made up 0.2% of Omni Partners US's portfolio in Q3 2021, its #96 holding.
  • Omni Partners US first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q2 2021 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.